School of Pharmacy and Bioengineering, Chongqing University of Technology, Chongqing, People's Republic of China.
Int J Nanomedicine. 2023 Apr 24;18:2127-2140. doi: 10.2147/IJN.S404486. eCollection 2023.
The immunosuppressive tumor microenvironment (TME) of solid tumors inhibits most drug delivery system-based nanomaterials from achieving deep penetration in tumor tissue and interferes with T cell activity in terms of differentiation and exhaustion, which is becoming a critical therapy hurdle for solid tumors. Therefore, developing a therapeutic strategy with abilities of rapid establishment of tumor-targeted cells, elimination of immune obstacles, and enhanced active immunization is very important, while is still a big challenge.
A new strategy was explored to enhance immune therapy via the conjugation of microRNA155 (miR) to the surface of therapeutic monocyte with graphene quantum dots (GQDs).
TME was reversed using surface-engineered monocyte immunotherapy via reprogramming pro-tumoral M2 TAMs into antitumor M1, and thus tumor elimination was dramatically enhanced.
Such a surface-engineered monocyte immunotherapy has been demonstrated to be well tolerated to intravenous administration and bio-compatible, showing the potential to be extended for the solid tumor treatment.
实体瘤的免疫抑制肿瘤微环境（TME）抑制了大多数基于药物输送系统的纳米材料在肿瘤组织中的深层渗透，并干扰了 T 细胞的分化和耗竭活性，这成为实体瘤治疗的一个关键障碍。因此，开发一种具有快速建立肿瘤靶向细胞、消除免疫障碍和增强主动免疫能力的治疗策略非常重要，但这仍然是一个巨大的挑战。
通过将 microRNA155 (miR) 与载有石墨烯量子点（GQDs）的治疗性单核细胞表面偶联，探索了一种增强免疫治疗的新策略。
通过将促肿瘤 M2 TAMs 重编程为抗肿瘤 M1，利用表面工程化的单核细胞免疫疗法逆转了 TME，从而显著增强了肿瘤消除。
这种表面工程化的单核细胞免疫疗法已被证明可耐受静脉注射和生物相容性，显示出在实体瘤治疗中扩展的潜力。
